Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507)... Read More

Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherap... Read More

Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety... Read More

Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Mo... Read More

Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in... Read More

Singapore Clinical Trial: An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BAY 3771249 as monotherapy or combination with other cancer treatments in participants with solid tumors harboring a KRAS G12D mutation

Singapore, Aug. 7 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and e... Read More

Kohinoor Foods to table results

Mumbai, Aug. 7 -- Kohinoor Foods will hold a meeting of the Board of Directors of the Company on 13 August 2026. Published by HT Digital Content Services with permission from Capital Market.... Read More

RI develops water technologies to tackle stronger El Nino

Jakarta, Aug. 7 -- Indonesia's National Research and Innovation Agency (BRIN) is advancing weather modification, desalination, and water purification technologies to strengthen water security as a str... Read More

Sparkle Gold Rock to conduct board meeting

Mumbai, Aug. 7 -- Sparkle Gold Rock will hold a meeting of the Board of Directors of the Company on 11 August 2026. Published by HT Digital Content Services with permission from Capital Market.... Read More

Aeonx Digital Technology to announce Quarterly Result

Mumbai, Aug. 7 -- Aeonx Digital Technology will hold a meeting of the Board of Directors of the Company on 12 August 2026. Published by HT Digital Content Services with permission from Capital Market... Read More

• ««
• «
• 1359
• 1360
• 1361
• 1362
• 1363
• 1364
• 1365
• 1366
• 1367
• 1368
• »
• »»